Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scarab Genomics and Lonza have signed a preferred marketing and sales agreement for Scarab Genomics’ Clean Genome E coli.
Subscribe to our email newsletter
As per the terms of the agreement, Lonza is expected to market Scarab Genomics’Clean Genome technology, giving Lonza customers full access to the platform for protein and plasmid DNA production.
Additionally, Lonza and Scarab Genomics will work together to develop new microbial expression technologies.
Scarab Genomics said that the optimised Clean Genome E coli strain is designed to provide enhanced genetic stability, improved metabolic efficiency and improved production yields which makes it a powerful system to establish commercially superior manufacturing processes for therapeutic proteins, plasmid DNA, and vaccines.
Scarab Genomics CEO Fred Blattner said that they were happy to be working with Lonza to bring the Clean Genome technology to a wider customer base.
Lonza Microbial Innovation & Strain Development head Joachim Klein said that the Scarab Genomics technology is a stable, high yielding platform that enables customers to lower their cost of goods and simplify their production process.
“Lonza is very pleased to be able to offer this microbial expression technology to our customers side by side with our existing XS Microbial Expression Technologies,” Klein said.